Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;37(5):809-825.
doi: 10.1016/j.hoc.2023.04.011. Epub 2023 Jun 1.

von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology

Nitin H Shirole  1 , William G Kaelin Jr  2
Affiliations
Review

von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology

Nitin H Shirole et al. Hematol Oncol Clin North Am. 2023 Oct.

Abstract

The most common form of kidney cancer is clear cell renal cell carcinoma (ccRCC). Biallelic VHL tumor suppressor gene inactivation is the usual initiating event in both hereditary (VHL Disease) and sporadic ccRCCs. The VHL protein, pVHL, earmarks the alpha subunits of the HIF transcription factor for destruction in an oxygen-dependent manner. Deregulation of HIF2 drives ccRCC pathogenesis. Drugs inhibiting the HIF2-responsive growth factor VEGF are now mainstays of ccRCC treatment. A first-in-class allosteric HIF2 inhibitor was recently approved for treating VHL Disease-associated neoplasms and appears active against sporadic ccRCC in early clinical trials.

Keywords: Belzutifan; Hypoxia-inducible factor; Kidney cancer; Renal cell carcinoma; von Hippel-Lindau disease.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Schematic representations of HIF1α, HIF2α, and HIF1β/ARNT. Created with BioRender.com.
Figure 2:
Figure 2:
Role of VHL in the regulation of HIFα abundance in normal and ccRCC cells under normoxia. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Sung H, et al. , Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209–249. - PubMed
    1. Siegel RL, et al. , Cancer statistics, 2022. CA Cancer J Clin, 2022. 72(1): p. 7–33. - PubMed
    1. Scelo G and Larose TL, Epidemiology and Risk Factors for Kidney Cancer. J Clin Oncol, 2018. 36(36): p. JCO2018791905. - PMC - PubMed
    1. Kovacs G, et al. , The Heidelberg classification of renal cell tumours. J Pathol, 1997. 183(2): p. 131–3. - PubMed
    1. Lopez-Beltran A, et al. , 2004 WHO classification of the renal tumors of the adults. Eur Urol, 2006. 49(5): p. 798–805. - PubMed

Publication types

MeSH terms

Substances